Business

SOPHiA GENETICS Announces Pricing of Initial Public Offering

BOSTON and LAUSANNE, Switzerland, July 22, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA, the creator of a global data pooling and knowledge sharing platform

articleSophia Genetics SaJuly 22, 20214/company/sophia-genetics-sa/news/sophia-genetics-announces-pricing-of-initial-public-offering
SOPHiA GENETICS Announces Pricing of Initial Public Offering

About this update from Sophia Genetics Sa

[{"type":"text","content":"BOSTON and LAUSANNE, Switzerland, July 22, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA, the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today the pricing of its initial public offering of 13,000,000 ordinary shares at a price of $18 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated fees and offering expenses payable by SOPHiA GENETICS SA, are expected to be approximately $234 million. In addition, SOPHiA GENETICS SA has granted the underwriters a 30-day option to purchase up to 1,950,000 additional ordinary shares. The ordinary shares are expected to begin trading on the Nasdaq Global Select Market on July 23, 2021 under the symbol “SOPH.” The offering is expected to close on July 27, 2021, subject to customary closing conditions. J.P. Morgan, Morgan Stanley, Cowen and Credit Suisse are acting as joint book-running managers for the offering. The offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (212) 834-4533 or by email at [email protected]; Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866) 718-1649 or by email at [email protected]; Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at [email protected]; and Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037 or by email at [email protected]. A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the sec...

More updates from Sophia Genetics Sa